In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapy: Cures Within Reach

This article was originally published in Start Up

Executive Summary

After rocky beginnings, there is increasing optimism about the potential for gene therapy to make an impact in rare disease. Promising data from late-stage clinical trials, improved safety, and the first Western regulatory approval of a gene therapy are now driving numerous initial public offerings, venture capital financings, and tie-ups with major pharmaceutical companies.

You may also be interested in...



Regen Medicine Drives Big Uptick In 2015 Start-Up Dealmaking

Biotech start-ups cut deals at a rapid pace in 2015, signing almost twice the number of alliances done in 2014. Regenerative medicine was prominent in key partnerships.

Biopharma Quarterly Dealmaking Statistics, Q2 2015

Q2 biopharma financing reached $15.4 billion, a slight increase over the previous quarter; leading the M&A activity was CVS' $11.8 billion buy of Omnicare; and AstraZeneca and Juno were the two most active dealmakers in cancer immunotherapy, a popular therapeutic focus of Q2 alliances.

Renova’s Gene Therapy To Reverse Heart Remodeling In CHF

Reversing the “remodeling” of the heart in congestive heart failure with an investigational gene therapy is one of the aims of the San Diego-based biotech that is planning late-stage clinical development.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel